Three-Axis Wearable Adaptive Vestibular Stimulator

Status Recruiting

Clinical Trial Summary

The purpose of this study is to improve current galvanic vestibular stimulation (GVS) technology to ease the motion sickness often associated with virtual reality (VR) simulation.

Clinical Trial Description

The Three-Axis Wearable Adaptive Vestibular Stimulator (3WAVeS) technology that combines galvanic vestibular stimulation (GVS) and Virtual Reality (VR) will not only increase VR-based simulation realism and presence, but will also mitigate the motion sickness often associated with VR simulation by re-coupling the vestibular and ocular inputs to the VR user. Additionally, due to GVS technology's ability to accurately provide continuous inputs to the vestibular system, 3WAVeS can intentionally simulate high-fidelity effects of spatial disorientation for training purposes. ;

Study Design

Related Conditions & MeSH terms

Motion Sickness

Clinical Trial Details

NCT number	NCT06106256
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Recruiting
Phase	N/A
Start date	November 15, 2023
Completion date	June 2024

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04196933` - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma	N/A
Recruiting	`NCT06128707` - Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
Completed	`NCT05611814` - Preliminary Evaluation of an Osteopathic Manipulative Treatment (OMT) to Prevent Motion Sickness Symptoms	N/A
Completed	`NCT02839135` - A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.	Phase 1
Completed	`NCT04420949` - Sensory Training for Visual Motion Sickness	N/A
Completed	`NCT04184115` - Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness	Phase 3
Completed	`NCT03988530` - Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects	Phase 3
Terminated	`NCT04219982` - DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness	Phase 2/Phase 3
Terminated	`NCT02155309` - Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray	Phase 2/Phase 3
Completed	`NCT04947423` - Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion	Phase 3
Recruiting	`NCT05903924` - Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness	Phase 3
Recruiting	`NCT04999449` - Nebulizer Delivery of Intranasal Scopolamine	Phase 1
Recruiting	`NCT05886660` - Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance	Phase 2
Completed	`NCT03755596` - Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness	Phase 4
Recruiting	`NCT05628220` - Motion Sickness Desensitization Using VR	N/A
Recruiting	`NCT06138613` - Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness	Phase 3
Completed	`NCT04327661` - Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness	Phase 3
Completed	`NCT06232785` - Gynecologic Endoscopic Surgery of Female Motion Sickness Patients	Phase 4
Completed	`NCT06056622` - Motion Sickness Rehabilitation for Virtual Reality	N/A
Withdrawn	`NCT04331561` - Sensory Training for Orientation and Balance	N/A